HUTCHMED secures a second FDA Orphan Drug Designation for sovleplenib, expanding its development into autoimmune hemolytic anemia (AIHA).
Written By: Kalyani Boharapi, M. Pharm (RA)
Reviewed By: Pharmacally Editorial Team
HUTCHMED (China) Limited announced on November 4, 2026, that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to sovleplenib for the treatment of autoimmune hemolytic anemia (AIHA). This marks the second FDA orphan designation for the investigational drug, following its designation for primary immune thrombocytopenia (ITP) in October 2026.
Sovleplenib is an investigational, selective oral spleen tyrosine kinase (Syk) inhibitor being developed for immune-mediated diseases and hematological malignancies. The latest designation extends its regulatory development pathway into another rare autoimmune blood disorder, although it does not constitute marketing approval or establish clinical efficacy in AIHA.
FDA Orphan Drug Designation and Development Incentives
The FDA’s Orphan Drug Designation programme supports the development of medicines intended to treat, diagnose or prevent rare diseases affecting fewer than 200,000 people in the United States.
If approved for the designated indication, eligible medicines may receive seven years of US market exclusivity, alongside other development incentives, including tax credits for qualified clinical trials, Prescription Drug User Fee Act (PDUFA) user fee waivers and specialized regulatory guidance from the FDA during clinical development.
For sovleplenib, the designation provides regulatory and potential financial incentives for its further development in AIHA. However, orphan designation does not demonstrate therapeutic benefit, establish safety or guarantee subsequent regulatory approval.
AIHA: Disease Background and Mechanism of Action
AIHA is an autoimmune disorder characterized by the destruction of red blood cells (RBCs) due to antibodies directed against them. The disease has an estimated annual incidence of 0.8–3.0 cases per 100,000 adults and a prevalence of approximately 17 per 100,000 adults. The reported death rate is 8–11%, although this estimate should be interpreted in the context of the underlying studies. Warm autoimmune hemolytic anemia (wAIHA) is the most common subtype, accounting for approximately 75–80% of adult AIHA cases.
Sovleplenib is a selective Syk inhibitor designed for once-daily oral administration. Syk plays an important role in B-cell receptor and Fc receptor signalling, pathways involved in immune-cell activation and antibody-mediated responses. Its inhibition represents the pharmacological approach being investigated for sovleplenib across autoimmune disorders and hematological malignancies.
Clinical Development and Regulatory Status
In China, HUTCHMED has submitted New Drug Applications (NDAs) for sovleplenib in primary ITP and warm AIHA. Both applications are currently under review by the National Medical Products Administration (NMPA).
The submissions are supported by positive results from two pivotal clinical studies: ESLIM-01, a Phase 3 trial evaluating sovleplenib in primary ITP (NCT05029635), and ESLIM-02, a Phase II/III trial evaluating the drug in warm AIHA (NCT05535933).
These applications represent separate regulatory development milestones in China and should not be conflated with the US orphan designation. HUTCHMED retains worldwide rights to sovleplenib and continues to advance its development across immune-mediated indications.
Clinical Significance
The second FDA Orphan Drug Designation expands sovleplenib’s regulatory positioning beyond primary ITP into AIHA, adding another rare autoimmune blood disorder to its development programme. The designation is particularly relevant from a development perspective because it provides potential incentives for advancing the drug through clinical development and subsequent regulatory evaluation in the United States.
However, the regulatory milestone should be distinguished from evidence of clinical benefit. The FDA designation does not indicate that sovleplenib has demonstrated efficacy in AIHA or that a US marketing application is imminent. Meanwhile, the ongoing NMPA reviews of its applications in primary ITP and warm AIHA represent the next important regulatory milestones for the programme in China.
Reference
HUTCHMED Announces Sovleplenib Granted US FDA Orphan Drug Designation for Autoimmune Hemolytic Anemia, Hutchmed, 05 November 2026
HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (wAIHA), ClinicalTrials.gov ID NCT05535933
About the Writer
Kalyani Boharapi (LinkedIn) is a pharmacy professional and healthcare writer currently pursuing an M.Pharm in Regulatory Affairs at Dr. D. Y. Patil College of Pharmacy, with interests in pharmaceutical regulations, drug development, and healthcare innovation. She has academic exposure to dossier preparation, scientific writing, and regulatory documentation. Kalyani has also completed certification courses in Generative AI, AI in Pharma, and Bioinformatics, and actively participates in pharmaceutical conferences to stay updated with emerging trends and advancements in the healthcare and pharmaceutical industry.